Follow

Brighter receives SEK 21 million from a directed share issue

15 September 2020 - 19:40

With authorization from the Annual General Meeting on June 15 2020, Brighter’s Board of Directors have decided to carry out a share issue directed to the company Unwrap Finance Nordic AB.

The subscription price is SEK 2.84283, which corresponds to a discount of 10 percent compared with the volume weighted average price of the share during the period August 3 to September 11.

The purpose of the share issue is to strengthen the company's financial position in the ongoing commercialization phase, during which market approval processes have been initiated in several countries. The prioritized markets are Sweden, UAE and Indonesia. The Board of Directors have resolved to deviate from the shareholders’ pre-emption rights to ensure the most time and cost-effective financing of its continued commercialization.

“Through this share issue, combined with the TO4 warrants that have just been exercised, the company receives more than SEK 40 million, which will be used to support the company's ongoing commercial initiatives in the Middle East and Southeast Asia. We are putting all our focus into market approvals and on securing revenue-generating agreements right now,” says Henrik Norström, CEO of Brighter.

The number of shares in the Company increases by 7,387,005, to a total of 217,291,255. The share capital increases by SEK 369,350.25 to a total of SEK 10,864,562.75.

For further information, please contact:

Please contact ir@brighter.se with any questions. Based on questions received, the company will publish a Q&A on its website.

Henrik Norström, CEO
+46 733 40 30 45

henrik.norstrom@brighter.se

Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. 
The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 19:40 CET on September 15, 2020.

Provided by: Cision
Nasdaq First North GM (Sweden)
Brighter AB
Brighter AB develops technical and digital medical devices with a primary area of application in the treatment of diabetes. The company's Actiste products is a mobile-connected solution that can measure blood glucose, inject insulin, log treatment values, and share data over-the-air - all from the same device. Its Benefit Loop product is a cloud-based platform that links the physical collection of...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date